Healthcare & Life Sciences

Carboxylated Psilocybin Derivatives and Methods of Using (US12605361B2)

USPTO granted patent US12605361B2 to Enveric Biosciences Canada Inc. covering carboxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The patent contains 18 claims and is based on Application No. 18227688 filed July 28, 2023. This grant confers exclusive IP rights to the assignee and does not create compliance obligations for third parties.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor and Pharmaceutical Use Therefor

The USPTO granted patent US12605359B2 to THE KITASATO INSTITUTE on April 21, 2026, covering a low-molecular weight compound that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) functions. The patent protects the compound represented by formula (I), its pharmaceutically acceptable salts and solvates, and medicaments containing the PCSK9 inhibitor for prevention or treatment of PCSK9-related diseases and disorders. The patent contains 5 claims.

mTOR Inhibitor Compound for Neurodegenerative Diseases

The USPTO granted Patent US12605358B2 to ALIAD BIOPHARMA for a novel mTOR signaling pathway inhibitor compound. The invention was found to inhibit mTORC1 and mTORC2 activities, activate autophagy, and alleviate symptoms associated with Alzheimer's-type dementia in animal models. The patent covers pharmaceutical compositions for preventing or treating nervous system diseases including neurodegenerative diseases and mTORopathy.

PanTher Therapeutics Drug Delivery Device Patent (US12605356B2)

The USPTO granted patent US12605356B2 to PanTher Therapeutics, Inc. covering implantable and biodegradable drug delivery devices for direct delivery of active pharmaceutical ingredients to pancreatic tumor tissue. The devices feature a two-layer design where one layer contains the API with a biodegradable polymer and a second layer prevents API release away from the target tissue. The patent names Laura Indolfi and Margaret Lashof-Sullivan as inventors.

HA-Paclitaxel Conjugate Patent for Treatment of Mesothelioma

USPTO granted Patent US12605355B2 to Fidia Farmaceutici S.p.A. covering HA-paclitaxel conjugate compositions for loco-regional treatment of malignant mesothelioma. The patent, with 13 claims, covers malignant pleural, pericardial, and peritoneal mesothelioma applications, with priority dating to the April 7, 2021 filing.

PDIA4 Inhibitors Treat Diabetes, Preserve Beta Cells

USPTO has granted Patent US12605353B2 to Academia Sinica, covering disulfide-isomerase A4 (PDIA4) inhibitors for inhibiting pancreatic beta-cell pathogenesis and treating diabetes. The patent discloses drug candidates with IC50 values ranging from 4 micrometers to 300 nanomolars that augment insulin secretion from pancreatic beta-cells. Pharmaceutical companies developing diabetes or metabolic disease therapeutics should monitor this IP landscape for potential licensing, freedom-to-operate, or R&D pathway considerations.

Chimeric Klebicins - Bactoclear Holdings

The USPTO granted US Patent 12,606,598B2 to Bactoclear Holdings PTE, Ltd. covering chimeric klebicins — engineered antimicrobial proteins combining translocation, receptor-binding, and bactericidal domains from different klebicin sources. The patent includes 15 claims and covers compositions, kits, and methods of use designed to improve target cell range and bactericidal activity against bacterial pathogens.

Evaxion Biotech Pseudomonas Aeruginosa Vaccine Patent

The USPTO granted patent US12606597B2 to Evaxion Biotech A/S on April 21, 2026. The patent covers immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors, and transformed cells useful for expression of the proteins, along with methods for prophylaxis of infection. The patent contains 12 claims.

Macrocyclic Compounds, SRC MET Inhibitor, Cancer Treatment

USPTO granted patent US12606571B2 to Turning Point Therapeutics, Inc. for macrocyclic compounds that inhibit SRC and MET and/or CSF1R, pharmaceutical compositions thereof, and methods of using such compounds to treat cancer. The patent contains 9 claims and was granted on April 21, 2026.

Recombinant AAV Vectors for Treating Parkinson's, MSA, Gaucher's Disease - US12605467B2

USPTO granted patent US12605467B2 to Shanghai Vitalgen Biopharma Co., Ltd. on April 21, 2026, covering recombinant adeno-associated viral (rAAV) vectors encoding aromatic L-amino acid decarboxylase (AADC), glucocerebrosidase (GBA1), and neurotrophic factors (CDNF or GDNF) for treating neurodegenerative disorders including Parkinson's disease, multiple system atrophy, and Gaucher's disease. The patent contains 14 claims and names three inventors.

JAK Inhibitor Compounds, Galderma Holding SA Patent

USPTO granted patent US12606559B2 to Galderma Holding SA on April 21, 2026, covering novel JAK inhibitor compounds of formula (I), methods of synthesis, and methods of using these compounds to treat diseases, conditions, and disorders. The patent contains 14 claims.

Substituted Indole Compounds With Inhibitory Activity for Treating Acute Renal Failure

USPTO granted patent US12606557B2 to the University of Pittsburgh-of the Commonwealth System of Higher Education on April 21, 2026. The patent covers substituted indole compounds and compositions for treating or preventing acute renal failure, as well as infectious diseases and cancer. The application (No. 17927406) was filed on May 27, 2021, with 17 claims and CPC classification C07D 471/04.

TYK2 Inhibitor Compound, BeOne Medicines, US12606556B2

The USPTO granted Patent US12606556B2 to BeOne Medicines I GmbH on April 21, 2026, covering a TYK2 inhibitor compound (Formula I) and its pharmaceutical uses for treating inflammatory or autoimmune diseases. The patent contains 17 claims and classifies under CPC C07D 471/04. Inventors are Qiuwen Wang, Yunhang Guo, and Zhiwei Wang. The patent creates intellectual property rights but does not impose compliance obligations on third parties.

ONCO3R B2 Patent - Heterocyclic Compounds and Pharmaceutical Compositions for Disease Treatment

The USPTO granted US Patent 12,606,554 B2 to ONCO3R Therapeutics BV on April 21, 2026. The patent covers heterocyclic compounds according to Formula I and pharmaceutical compositions for treating inflammatory, autoinflammatory, autoimmune, proliferative, fibrotic diseases, transplant rejection, and diseases involving impairment of cartilage or bone turnover, as well as conditions associated with hypersecretion of IL-6, TNFα, interferons, IL-12 and/or IL-23. The patent contains 19 claims and was filed on May 25, 2020.

Crystalline Forms of Formula (I) Compounds for Cancer Treatment

The USPTO granted Patent US12606553B2 to Foghorn Therapeutics Inc., covering crystalline forms of a formula (I) compound and compositions containing those forms. The patent also protects methods of using the crystalline forms for treating cancer in subjects, including administration of an effective amount of the compound. The patent, classified under CPC C07D 417/14 (organic chemistry, heterocyclic compounds), contains 11 claims.

Salt of Tetrahydroisoquinoline Derivative, Preparation Method, Medical Use

USPTO granted patent US12606551B2 to Zhejiang Hisun Pharmaceutical Co., Ltd. covering a salt form of (S)-2-(6-fluorobenzo[d]oxazol-2-yl)-6-methoxy-5-((5-methoxypyridin-2-yl))methoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, its preparation method, and pharmaceutical compositions containing it. The patent classifies the compound as an angiotensin II type-2 receptor antagonist. Four claims were allowed.

Anticholinergic Agents Patent US12606549B2, Rezubio Pharma

The USPTO granted US Patent 12606549B2 to Rezubio Pharmaceuticals Co., Ltd covering muscarinic acetylcholine receptor antagonist compounds (including M3 antagonists) and pharmaceutical compositions for treating hyperhidrosis. The patent contains 19 claims and names Yusheng Xiong and Hongping Guan as inventors.

Shenyang Sinochem Agrochemicals - Phenylisoxazoline Compound, US12606547B2

The USPTO granted Patent US12606547B2 to Shenyyang Sinochem Agrochemicals R&D Co., Ltd. covering a synthesis method for a phenylisoxazoline compound. The method uses 2-fluoro-4-chloro-5-methylaniline as a starting material, first synthesizing a uracil ring and then an isooxazoline ring to produce the target compound. The patent contains 8 claims and is classified under CPC C07D 413/10.

Organic Electronic Compound for Organic Electronic Element Patent Granted

The USPTO granted Patent US12606545B2 to DUK SAN NEOLUX CO., LTD. for a compound represented by Formula 1 used in organic electric elements. The invention comprises a first electrode, second electrode, and organic material layer, with applications in electronic devices. The patent claims nine claims covering the compound composition and its use in lowering driving voltage while improving luminous efficiency and lifetime.

MindSet Pharma Indole Derivative Serotonergic Patent Granted

USPTO granted patent US12606543B2 to MindSet Pharma Inc. on April 21, 2026. The patent covers indole derivatives as serotonergic agents useful for activation of serotonin receptors in cells and treating diseases, disorders, or conditions including psychosis, mental illnesses, and CNS disorders.

PPARg Modulators and Methods of Use

USPTO granted Patent US12606541B2 to Eisai R&D Management Co., Ltd. on April 21, 2026. The patent covers 34 claims for PPARg modulators (compounds of Formula 1) and their methods of use, including pharmaceutical compositions containing these compounds. The patent was filed November 8, 2021, with application number 17521666.

Memorial Sloan Kettering DCN1-UBC12 Inhibitor Patent Granted

The USPTO granted US Patent 12605373B2 to Memorial Sloan Kettering Cancer Center on April 21, 2026. The patent covers substituted 1-phenyl-3-(piperidin-4-yl)urea analogs as inhibitors of DCN1-UBC12 interaction and DCN1-mediated cullin-RING ligase activity. The application (18596521) was filed March 5, 2024, with 14 claims allowed.

Expandable Intervertebral Cage Implant

USPTO granted patent US12605254B2 to inventor Robert Woodruff for an expandable intervertebral cage implant. The device features top and bottom plates with rotatable leaves, front and rear wedges, and a deployment mechanism that rotates leaves into a deployed position while increasing cage width and height. The mechanism also allows variation of the lordosis angle by moving one wedge while keeping the other stationary.

Expandable Corpectomy Modular Endplate Connection

The USPTO granted Patent US12605253B2 to Astura Medical Inc for an expandable corpectomy modular endplate connection system. The invention relates to vertebral body replacement devices featuring a quick-connecting removable endplate mechanism. The patent, filed on October 18, 2024, contains 9 claims and names Ross Dusterhoft and Thomas Purcell as inventors.

Aurora Spine Bone Density-Matched Orthopedic Implant Method Patent Grant

The USPTO granted Patent US12605252B2 to Aurora Spine, Inc. on April 21, 2026, covering a method of selecting and implanting orthopedic implants matched to a patient's bone density as determined by DEXA scan T-scores. The patent names inventors Trent James Northcutt and Laszlo Garamszegi and contains 16 claims.

US12605250B2 Stabilizing Sacroiliac Joints Patent

USPTO granted US Patent 12605250B2 to Tenon Medical, Inc. covering prostheses and methods for stabilizing dysfunctional sacroiliac (SI) joints. The patent describes devices configured for posterior trajectory advancement via surgically created pilot openings, featuring elongated edge sections and bridge sections. The patent includes 11 claims and CPC classifications spanning A61F 2002/30995, A61F 2/30988, A61F 2/4455, and A61F 2/447.

Implantable Electromagnetic Field Generator for Orthopedic Therapy

The USPTO granted patent US12605249B2 to Pulsar Medtech Ltd. on April 21, 2026. The patent covers an implantable electromagnetic field generator for orthopedic therapy, comprising an anchor with an affixing portion, a coil, an electronics module, and a power source that generates therapeutic electromagnetic fields for soft tissue repair.

California Clears 215,000 Convictions, Disrupts $1.2B Illicit Cannabis Activity

California has cleared more than 215,000 cannabis convictions and disrupted $1.2 billion in illicit cannabis activity over the past decade, marking 10 years since voters approved Proposition 64 in 2016. The announcement was made by Governor Gavin Newsom and the California Department of Cannabis Control. This is a commemorative press release summarizing the state's cannabis legalization outcomes.

fMRI Study, BPD Adolescents, Quebec: Feasibility Study NCT07540429

NIH ClinicalTrials.gov registered a new feasibility study (NCT07540429) investigating impaired social cognition and cognitive control associated with borderline personality disorder (BPD) in adolescents using functional magnetic resonance imaging (fMRI). The Franco-Canadian study is conducted in Quebec and includes participants with BPD, ADHD, and healthy controls. The study aims to explore neural correlates of BPD and related clinical disorders.

APTA Alternative Peripheral TAVI Accesses Registry Observational Study

The NIH ClinicalTrials.gov registry records an observational multi-center study investigating alternative peripheral access routes for transcatheter aortic valve implantation (TAVI) in high and medium-risk patients with aortic stenosis who are contraindicated for transfemoral TAVI. The APTA registry will include patients treated at Upper Silesian Medical Center, Katowice and other hospitals.

Observational Study of Folate Receptor Alpha Prevalence in Ovarian Cancer, 1,000 Participants

The National Institutes of Health registered a new observational study (NCT07539844) to evaluate folate receptor alpha (FRa) prevalence in approximately 1,000 adult female participants with ovarian cancer across intercontinental countries. Archived tissue biopsies will be tested for FRa via immunohistochemistry, with data collected retrospectively while testing proceeds prospectively. No investigational drug will be administered; the study duration is approximately one year.

Belimumab Phase 2 Study for Highly Sensitized Transplant Candidates

The NIH ClinicalTrials.gov registry has published a Phase 2 clinical study (NCT07539857) evaluating belimumab (Benlysta) in highly sensitized kidney transplant candidates. The trial aims to determine whether belimumab improves detection of circulating HLA-specific memory B cells to support safer donor organ allocation. Participants will receive belimumab treatment and undergo memory B-cell profiling to evaluate potential adjustment of unacceptable HLA specificities.

Effect of Transcutaneous Tibial Nerve Stimulation Combined With Exercise on High Post-Void Residual Urine Volume in Post-Menopausal Women

NIH has registered a clinical trial (NCT07538895) on ClinicalTrials.gov evaluating the effect of transcutaneous tibial nerve stimulation combined with exercise on high post-void residual urine volume in post-menopausal women. The randomized study will enroll 60 participants across two groups over 12-week physiotherapy sessions. This is an informational study registration with no compliance or reporting obligations.

GH001 Aerosol Phase 1 Trial - Pharmacokinetics and Safety in Healthy Subjects

The NIH ClinicalTrials.gov registry records a Phase 1 clinical trial (NCT07540494) investigating the pharmacokinetic profile and safety/tolerability of GH001 (5-methoxy N,N-dimethyltryptamine) delivered via a proprietary aerosol delivery system in healthy adult subjects. The single-dose study is registered with intervention type and primary endpoints documented.

Comparison of Endoscopic and Open Breast-Conserving Surgery in Breast Cancer

NIH registered a randomized controlled trial (NCT07539545) comparing minimal accessory-incision-assisted endoscopic breast-conserving surgery (M-E-BCS) with conventional open breast-conserving surgery (C-O-BCS) in breast cancer patients. The multicenter, open-label trial evaluates operative time, economic effects, surgical complications, postoperative aesthetics (BREAST-Q, Harris, SCAR-Q, and Ueda scores), and oncological safety outcomes including margin status and local recurrence-free survival.

Phase 1 Diabetes Trial AD-123 Safety PK Study

NIH ClinicalTrials.gov registered a new Phase 1 clinical trial (NCT07538466) on April 20, 2026. The study evaluates the safety and pharmacokinetics of investigational drug AD-123 compared to coadministration of AD-1231 and AD-1232 in patients with Diabetes Mellitus.

Randomized Trial of Dexamethasone Injection for Postoperative Pain After Third Molar Surgery

The NIH ClinicalTrials.gov registry published a new study entry (NCT07538375) for a randomized clinical trial evaluating dexamethasone injection effectiveness for reducing postoperative pain following surgical removal of impacted mandibular third molars. The trial enrolls patients at 28 Military Dental Centre, Lahore, comparing standard local anesthesia alone against local anesthesia plus dexamethasone injection, with pain assessed via Visual Analogue Scale at 24, 48, and 72 hours post-surgery.

Neuroathletic vs Reactive Training in American Football Players

NIH's ClinicalTrials.gov has registered NCT07540247, a randomized controlled trial comparing neuroathletic training, reactive training, and routine team training in American football players aged 18-30. The 4-week intervention involves two additional exercise sessions per week for the active groups, with assessments covering Y Balance Test, Functional Movement Screen, Reactive Balance Test, core endurance, and flexibility. No compliance obligations are created by this study registration.

CSF-1R Kinase Inhibitor Patent Grant

USPTO granted patent US12605375B2 to Shanghai Runshi Medical Technology Co., Ltd. covering the use of a CSF-1R kinase inhibitor compound for treating diseases related to CSF-1R kinase signal transduction and for regulating immunization. The patent claims 8 total claims. The compound demonstrated superior inhibition of CSF-1R kinase activity and anti-tumor efficacy compared to marketed drug Pexidartinib in preclinical studies.

CP2c-Targeting Peptide Anticancer Agent Patent Grant

USPTO granted patent US12605453B2 to Industry-University Cooperation Foundation Hanyang University on April 21, 2026, covering a CP2c-targeting peptide-based anticancer agent. The peptide binds to transcription factor CP2c to inhibit the formation of CP2c homotetramers and CP2c/CP2b/PIAS1 heterohexamers, inducing cancer cell-specific cell death. A fatty acid is bound to the peptide for in vivo stability. The patent contains 5 claims.

PSMA-Targeted Cancer Immunotherapy Patent Granted to Methodist Hospital

The USPTO granted patent US12605446B2 to The Methodist Hospital covering engineered cells with chimeric antigen receptors (CARs) targeting PSMA for prostate cancer treatment. The patent, filed August 20, 2021, contains 15 claims and names Bin He as inventor. This grant confers exclusive IP rights for PSMA-targeted CAR-T immunotherapies in the United States.

Immunogenic Trimers - International AIDS Vaccine Initiative

The USPTO granted Patent US12605441B2 to International AIDS Vaccine Initiative, Inc. on April 21, 2026. The patent covers immunogenic trimer compositions including PGT121-germline-targeting designs, trimer stabilization designs, and trimer nanoparticle configurations for use in immunization regimens against HIV.

High-activity Blood Coagulation Factor XI Mutant Ala570Thr Patent

The USPTO granted patent US12605430B2 to Ruijin Hospital Shanghai Jiaotong University School of Medicine for a high-activity blood coagulation factor XI mutant (Ala570Thr/A570T). The mutant demonstrates resistance to physiological inhibitors after activation and exhibits strong blood coagulation activity. The patent covers nucleotide sequences (SEQ ID NOs: 1-4), amino acid sequence (SEQ ID NO: 5), and applications for treating hemorrhagic diseases through gene therapy, gene editing, and recombinant protein replacement treatments.

TNF Muteins and Uses Thereof

USPTO granted Patent US12605425B2 to Oxford University Innovation Limited for tumour necrosis factor (TNF) muteins that function as selective agonists of tumour necrosis factor receptor 1 (TNFR1). The patent covers compositions comprising these TNF muteins, methods of treating or detecting tumours, and related nucleic acids and host cells. This is a routine patent grant conferring exclusive rights to the assignee with no immediate compliance obligations for other parties.

Tetrapeptide Compositions for Treating Eye Disorders

The USPTO granted patent US12605422B2 to S.I.S SHULOV INNOVATIVE SCIENCE LTD. on April 21, 2026, covering tetrapeptide pharmaceutical compositions for treating degenerative, age-related, and trauma-induced disorders of the eye. The patent, application number 17762984, was filed September 23, 2020, and contains 20 claims classified under CPC codes A61K 38/07, A61P 25/28, and C07K 5/1024.

Engineered Probiotics for Treatment and Immunity Against Viruses

The USPTO granted Patent US12605413B2 to the University of Cincinnati covering an engineered probiotic bacterium comprising heterologous nucleic acid encoding an anti-spike glycoprotein nanobody of a coronavirus. In one embodiment, the bacterium is Escherichia coli Nissle 1917 with the nanobody appearing on the bacterial surface. The patent contains 9 claims and was filed on April 19, 2021.

Mitochondria-enriched Genetically Engineered Cells and Uses Thereof

The USPTO granted Patent No. US12605410B2 to Minovia Therapeutics Ltd. covering pharmaceutical compositions of mitochondrially-enriched genetically engineered T cells and methods of using such cells to treat diseases and disorders. The patent, with 18 claims, was filed on March 30, 2021. This IP grant gives Minovia enforceable rights to its cell engineering technology through the patent term.

Peptide Inhibitors for SARS-CoV-2 Methyltransferase

The USPTO granted Patent US12605423B2 to United Arab Emirates University for synthetic peptide inhibitors designed to inhibit SARS-CoV-2 replication through targeting of Methyltransferase complexes (NSP10/NSP16 and NSP10/NSP14) for COVID-19 treatment. The patent covers Peptide P3, a synthetic analog of amino acids 89-96 of the SARS-CoV-2 non-structural protein 10 (NSP10), modified to enhance cell membrane penetration.

Methods of treating relapsing multiple sclerosis using fenebrutinib 200mg twice daily

USPTO issued Patent US12605376B2 to Genentech, Inc. covering methods of treating Relapsing Multiple Sclerosis using fenebrutinib, a Bruton's tyrosine kinase inhibitor. The patent protects administration of approximately 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof. The patent contains 17 claims and is classified under CPC codes A61K 31/4985, A61P 37/00, and A61P 25/00.

CCBHC-Expansion Grant Program Evaluation Information Collection

SAMHSA has published a 30-day notice and request for public comment on a proposed new information collection for the Certified Community Behavioral Health Clinic (CCBHC)-Expansion Grant Program Evaluation. The collection involves 298 respondents submitting de-identified Electronic Health Record data twice over an 8-hour response period each, totaling 4,768 burden hours at an estimated cost of $281,645.76. Comments are due June 22, 2026.